Centessa Pharmaceuticals plc (CNTA) — Estimates & Forecasts
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
Popular:
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income | $-216M | $-151M | $-236M |
| EPS (Diluted) | $-2.31 | $-1.57 | $-2.06 |
| YoY Growth | — | — | — |
| Net Margin | — | -2204.7% | — |
| Metric | 2024A | 2025E | 2026E | 2027E | 2028E |
|---|---|---|---|---|---|
| Revenue | — | $7M | $12M | $6M | $6M |
| Net Income | $-236M | $-79M | $-73M | $-3M | $-3M |
| EPS (Diluted) | $-2.06 | $-0.63 | $-0.53 | $-0.02 | $-0.02 |
| Free Cash Flow | $-142M | $-2M | $-4M | $-2M | $-2M |
Treat point estimates cautiously; use wider scenario ranges and position sizing discipline.
Centessa Pharmaceuticals plc's projected EPS for the next fiscal year is $-0.63. This estimate blends our quantitative model with Wall Street analyst consensus and carries a confidence score of 45/100. The model factors in revenue trajectory, margin path, and share buyback trends to arrive at this figure.
Our scenario-based model produces three price targets for Centessa Pharmaceuticals plc: Bear case $N/A, Base case $N/A, and Bull case $N/A. These targets are derived by applying the median historical P/E ratio to forward EPS estimates under each growth scenario. They are not buy/sell recommendations.
Centessa Pharmaceuticals plc's projected revenue growth for the next fiscal year is -50.2%, reaching approximately $0.0B in total revenue. Growth estimates are probability-weighted and blend analyst consensus with our CAGR extrapolation model. Outer years (FY+3, FY+4) fade toward industry median growth rates.
Accuracy depends on several measurable factors. Our model confidence score of 45/100 is computed from revenue predictability (25% weight), margin stability (20%), historical earnings beat rate (20%), data depth (15%), analyst coverage (10%), and model-consensus agreement (10%). Stable margins provide a consistent baseline. No forecast model is perfect — always cross-reference with your own analysis.
Centessa Pharmaceuticals plc's forward operating margin is estimated at -50.0% for the next fiscal year. The margin trend is currently "stable". Our model tracks margin mean-reversion patterns and adjusts for sector-specific cost dynamics. Operating leverage is a key driver of EPS growth beyond top-line revenue expansion.
The v2 model uses a multi-step process: (1) Revenue is projected via blended CAGR with probability weighting, (2) Operating and net margins follow a mean-reversion path calibrated to sector norms, (3) EPS is derived from net income divided by projected diluted shares (accounting for buyback trends), (4) For FY+1 and FY+2, estimates are blended with analyst consensus based on coverage depth, (5) Price targets apply median historical P/E to forward EPS under bear/base/bull growth scenarios. All inputs are from public filings and third-party data providers.
The bear case ($N/A) assumes P25 revenue growth, worst-case margins, and multiple compression. Key risks include: unexpected margin contraction, revenue deceleration below model floor, regulatory headwinds, macro deterioration, or competitive disruption. A confidence score below 60 suggests higher estimate volatility. Always size positions according to the full scenario range, not just the base case.
Our model is above Wall Street consensus with a 61.7% gap. For FY+1, analyst estimates blend with our model at 37% analyst weight. By FY+3 and FY+4, estimates are purely model-driven as analyst coverage thins out at longer horizons.